Compare

CJC-1295 vs TB-500

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

CJC-1295

670 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 64% · Mixed 18% · Unfavorable overall 18%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Joint comfort
-59
Recovery
-110
Digestive comfort
-71
Skin appearance
1
Appetite control
-102

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Injection site reaction
-143
Anxiety
-30
Flushing
-106
Headache
-3
GI discomfort
-103

Self-reported dose per injection

Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg

Reports span 0.1–2 mg

0.1–0.2 mg
8
0.2–0.4 mg
11
0.4–0.6 mg
21
0.6–1 mg
15
1–2 mg
4

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing34stacking27side effects30cjc-129528

How repeat users are trending

Among repeat reporters, 59% said they felt similar to their last entry, 44% more positive, and 14% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 24 days · Based on 147 repeat reporters

TB-500

486 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 60% · Mixed 26% · Unfavorable overall 14%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Sleep quality
-43
Lean mass
-153
Joint comfort
-144
Recovery
-98
Digestive comfort
-47

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Water retention
-127
Appetite loss
-73
Injection site reaction
1
Anxiety
-102
Flushing
-48

Self-reported dose per injection

Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg

Reports span 0.1–2 mg

0.1–0.2 mg
8
0.2–0.4 mg
16
0.4–0.6 mg
19
0.6–1 mg
14
1–2 mg
4

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing50stacking38side effects26tb-50019

How repeat users are trending

Among repeat reporters, 55% said they felt similar to their last entry, 34% more positive, and 20% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 14 days · Based on 107 repeat reporters

Sources (10)

Published sources linked on the CJC-1295 and TB-500 wiki pages.

  1. PubMed

    Prolonged stimulation of growth hormone (GH) secretion after a single administration of CJC-1295

    Teichman SL, Neale A, Lawrence B, et al. J Clin Endocrinol Metab. 2006

    Source
    Wiki study page →
  2. PubMed

    Growth hormone-releasing peptides: clinical applications

    Ghigo E, Arvat E, Camanni F. Endocrine. 2008

    Source
    Wiki study page →
  3. ClinicalTrials.gov

    CJC-1295 growth hormone studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  4. PubMed

    Thymosin beta 4 and wound healing: a multifunctional peptide

    Goldstein AL, Kleinman HK. Expert Opin Biol Ther. 2010

    Source
    Wiki study page →
  5. PubMed

    Myocardial regeneration: expanding the repertoire of thymosin β4 in the ischemic heart

    Smart N, Riley PR. Ann N Y Acad Sci. 2012

    Source
    Wiki study page →
  6. ClinicalTrials.gov

    Thymosin beta-4 studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  7. PubMed

    Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications

    Goldstein AL, Hannappel E, Sosne G, et al. Expert opinion on biological therapy. 2012

    Source
    Wiki study page →
  8. PubMed

    Recombinant thymosin beta 4 can promote full-thickness cutaneous wound healing

    Li X, Zheng L, Peng F, et al. Protein expression and purification. 2007

    Source
    Wiki study page →
  9. PubMed

    Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians

    Mayfield CK, Bolia IK, Feingold CL, et al. Am J Sports Med. 2026

    Source
    Wiki study page →
  10. PubMed

    Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions

    Rahman OF, Lee SJ, Seeds WA. JAAOS Glob Res Rev. 2026

    Source
    Wiki study page →